Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas

S. Ulisse, E. Baldini, M. Toller, E. Marchioni, L. Giacomelli, E. De Antoni, E. Ferretti, A. Marzullo, F. M. Graziano, P. Trimboli, L. Biordi, F. Curcio, A. Gulino, F. S. Ambesi-Impiombato, M. D'Armiento

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We characterised the expression of the plasminogen activators (uPA and tPA), the uPA receptor (uPAR) and the PAs inhibitors (PAI-1 and PAI-2) in human thyroid cell lines derived from normal thyroid, follicular adenoma, follicular, papillary and anaplastic carcinomas. Urokinase PA activity was detected in the supernatant of normal thyrocytes and augmented in those of all tumour cells. Quantitative RT-PCR analysis showed that uPA, uPAR and PAI-1 mRNAs increased in all carcinoma cells. Similar results were found in 13 papillary thyroid carcinoma (PTC) tissues which were mirrored in Western blot experiments. A correlation was found between tumour size and uPA mRNA increase, and higher levels of uPA and uPAR mRNAs were found in metastatic PTC. In conclusion, thyroid carcinoma cell lines and PTC overexpress uPA, uPAR and PAI-1 and the correlation of uPA and its cognate receptor with tumour size and metastasis may suggest their potential prognostic relevance in thyroid cancer.

Original languageEnglish
Pages (from-to)2631-2638
Number of pages8
JournalEuropean Journal of Cancer
Volume42
Issue number15
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Papillary Carcinoma
Plasminogen
Plasminogen Activator Inhibitor 1
Tumor Cell Line
Thyroid Neoplasms
Thyroid Gland
Messenger RNA
Plasminogen Activator Inhibitor 2
Carcinoma
Cell Line
Neoplasms
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Adenoma
Western Blotting
Neoplasm Metastasis
Polymerase Chain Reaction
Papillary Thyroid cancer

Keywords

  • Human
  • Plasminogen activator inhibitors
  • Plasminogen activators
  • Thyrocyte
  • Thyroid tumours
  • Urokinase plasminogen activator receptor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. / Ulisse, S.; Baldini, E.; Toller, M.; Marchioni, E.; Giacomelli, L.; De Antoni, E.; Ferretti, E.; Marzullo, A.; Graziano, F. M.; Trimboli, P.; Biordi, L.; Curcio, F.; Gulino, A.; Ambesi-Impiombato, F. S.; D'Armiento, M.

In: European Journal of Cancer, Vol. 42, No. 15, 10.2006, p. 2631-2638.

Research output: Contribution to journalArticle

Ulisse, S, Baldini, E, Toller, M, Marchioni, E, Giacomelli, L, De Antoni, E, Ferretti, E, Marzullo, A, Graziano, FM, Trimboli, P, Biordi, L, Curcio, F, Gulino, A, Ambesi-Impiombato, FS & D'Armiento, M 2006, 'Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas', European Journal of Cancer, vol. 42, no. 15, pp. 2631-2638. https://doi.org/10.1016/j.ejca.2006.04.017
Ulisse, S. ; Baldini, E. ; Toller, M. ; Marchioni, E. ; Giacomelli, L. ; De Antoni, E. ; Ferretti, E. ; Marzullo, A. ; Graziano, F. M. ; Trimboli, P. ; Biordi, L. ; Curcio, F. ; Gulino, A. ; Ambesi-Impiombato, F. S. ; D'Armiento, M. / Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. In: European Journal of Cancer. 2006 ; Vol. 42, No. 15. pp. 2631-2638.
@article{370593689c194a00bf663b7e80031399,
title = "Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas",
abstract = "We characterised the expression of the plasminogen activators (uPA and tPA), the uPA receptor (uPAR) and the PAs inhibitors (PAI-1 and PAI-2) in human thyroid cell lines derived from normal thyroid, follicular adenoma, follicular, papillary and anaplastic carcinomas. Urokinase PA activity was detected in the supernatant of normal thyrocytes and augmented in those of all tumour cells. Quantitative RT-PCR analysis showed that uPA, uPAR and PAI-1 mRNAs increased in all carcinoma cells. Similar results were found in 13 papillary thyroid carcinoma (PTC) tissues which were mirrored in Western blot experiments. A correlation was found between tumour size and uPA mRNA increase, and higher levels of uPA and uPAR mRNAs were found in metastatic PTC. In conclusion, thyroid carcinoma cell lines and PTC overexpress uPA, uPAR and PAI-1 and the correlation of uPA and its cognate receptor with tumour size and metastasis may suggest their potential prognostic relevance in thyroid cancer.",
keywords = "Human, Plasminogen activator inhibitors, Plasminogen activators, Thyrocyte, Thyroid tumours, Urokinase plasminogen activator receptor",
author = "S. Ulisse and E. Baldini and M. Toller and E. Marchioni and L. Giacomelli and {De Antoni}, E. and E. Ferretti and A. Marzullo and Graziano, {F. M.} and P. Trimboli and L. Biordi and F. Curcio and A. Gulino and Ambesi-Impiombato, {F. S.} and M. D'Armiento",
year = "2006",
month = "10",
doi = "10.1016/j.ejca.2006.04.017",
language = "English",
volume = "42",
pages = "2631--2638",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "15",

}

TY - JOUR

T1 - Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas

AU - Ulisse, S.

AU - Baldini, E.

AU - Toller, M.

AU - Marchioni, E.

AU - Giacomelli, L.

AU - De Antoni, E.

AU - Ferretti, E.

AU - Marzullo, A.

AU - Graziano, F. M.

AU - Trimboli, P.

AU - Biordi, L.

AU - Curcio, F.

AU - Gulino, A.

AU - Ambesi-Impiombato, F. S.

AU - D'Armiento, M.

PY - 2006/10

Y1 - 2006/10

N2 - We characterised the expression of the plasminogen activators (uPA and tPA), the uPA receptor (uPAR) and the PAs inhibitors (PAI-1 and PAI-2) in human thyroid cell lines derived from normal thyroid, follicular adenoma, follicular, papillary and anaplastic carcinomas. Urokinase PA activity was detected in the supernatant of normal thyrocytes and augmented in those of all tumour cells. Quantitative RT-PCR analysis showed that uPA, uPAR and PAI-1 mRNAs increased in all carcinoma cells. Similar results were found in 13 papillary thyroid carcinoma (PTC) tissues which were mirrored in Western blot experiments. A correlation was found between tumour size and uPA mRNA increase, and higher levels of uPA and uPAR mRNAs were found in metastatic PTC. In conclusion, thyroid carcinoma cell lines and PTC overexpress uPA, uPAR and PAI-1 and the correlation of uPA and its cognate receptor with tumour size and metastasis may suggest their potential prognostic relevance in thyroid cancer.

AB - We characterised the expression of the plasminogen activators (uPA and tPA), the uPA receptor (uPAR) and the PAs inhibitors (PAI-1 and PAI-2) in human thyroid cell lines derived from normal thyroid, follicular adenoma, follicular, papillary and anaplastic carcinomas. Urokinase PA activity was detected in the supernatant of normal thyrocytes and augmented in those of all tumour cells. Quantitative RT-PCR analysis showed that uPA, uPAR and PAI-1 mRNAs increased in all carcinoma cells. Similar results were found in 13 papillary thyroid carcinoma (PTC) tissues which were mirrored in Western blot experiments. A correlation was found between tumour size and uPA mRNA increase, and higher levels of uPA and uPAR mRNAs were found in metastatic PTC. In conclusion, thyroid carcinoma cell lines and PTC overexpress uPA, uPAR and PAI-1 and the correlation of uPA and its cognate receptor with tumour size and metastasis may suggest their potential prognostic relevance in thyroid cancer.

KW - Human

KW - Plasminogen activator inhibitors

KW - Plasminogen activators

KW - Thyrocyte

KW - Thyroid tumours

KW - Urokinase plasminogen activator receptor

UR - http://www.scopus.com/inward/record.url?scp=33749153201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749153201&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.04.017

DO - 10.1016/j.ejca.2006.04.017

M3 - Article

VL - 42

SP - 2631

EP - 2638

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 15

ER -